InvestorsHub Logo
icon url

shadolane

02/05/19 12:26 PM

#175075 RE: bogatie #175069

They did their due diligence. They knew who was on the panel and the affiliations.

It wasn't an oversight.
icon url

IgnoranceIsBliss

02/05/19 1:23 PM

#175081 RE: bogatie #175069

I fully expect to see Nissen and Kastelein on an ADCOM panel if it happens.
icon url

sts66

02/05/19 3:01 PM

#175097 RE: bogatie #175069

I passed it to investor relations and perhaps not surprisingly, they were aware of the post and it contents



Have to admit I'm a bit surprised about this - given the quantity of posts that we get here, it must take Elisabeth half of her Mondays to catch up on posts, and a couple hours a day to keep up during the week. I know other biotech employees read certain MBs, but they have relatively low posting volumes - sometimes this board is in the top 3 on IHUB.

In any case, good to know they're already aware of this stuff - but I hope they save it for the sNDA and don't talk about it at the ACC.

icon url

north40000

02/05/19 3:19 PM

#175100 RE: bogatie #175069

Your post has me confused re the discussion about Hiatt.

"...W. Hiatt even started discussing how he didn't think the REDUCE-IT primary end-point wasn't correct...."

The double negative suggests to me that he thought that the REDUCE-IT primary end-point was correct. If so, where does the controversy arise?